| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/14/2002 | CA2415333A1 Adenovirus e1b-55k single amino acid mutants and methods of use |
| 02/14/2002 | CA2406961A1 Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions |
| 02/14/2002 | CA2386103A1 Vascular endothelial growth factor 2 |
| 02/14/2002 | CA2385746A1 Method |
| 02/13/2002 | EP1179733A1 Compounds and methods for diagnosis of leishmaniasis |
| 02/13/2002 | EP1179590A1 Meg-3 protein |
| 02/13/2002 | EP1179588A1 Human brain carboxypeptidase b |
| 02/13/2002 | EP1179540A1 Novel polypeptide |
| 02/13/2002 | EP1179539A1 Novel protein having hemolytic activity and gene encoding the protein |
| 02/13/2002 | EP1179538A1 Peptides blocking response to chemical substances or thermal stimuli or nociceptor inflammation mediators and compositions containing said peptides |
| 02/13/2002 | EP1179350A2 Encapsulated cell system for implantation into the human CNS |
| 02/13/2002 | EP1179348A2 Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases |
| 02/13/2002 | EP1179347A1 Liver function controlling agents |
| 02/13/2002 | EP1179093A1 Expression of ets-domain proteins in cancer |
| 02/13/2002 | EP1179090A1 Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms |
| 02/13/2002 | EP1179078A1 Starch granules containing a recombinant polypeptide of interest, method for obtaining same and uses |
| 02/13/2002 | EP1179068A1 Interleukin-1 hy2 materials and methods |
| 02/13/2002 | EP1179067A1 Neuroprotective properties of gdf-15, a novel member of the tgf-beta superfamily |
| 02/13/2002 | EP1179066A2 Extracellular signaling molecules |
| 02/13/2002 | EP1179065A2 Full-length molecules expressed in human tissues |
| 02/13/2002 | EP1179064A2 Secreted polypeptides and corresponding polynucleotides |
| 02/13/2002 | EP1179063A2 Genes expressed in hippocampus |
| 02/13/2002 | EP1179062A2 Nucleic acids and proteins with p53 activity and altered tetramerization domains |
| 02/13/2002 | EP1179061A1 Methods for treating tumors using antiangiogenic compounds |
| 02/13/2002 | EP1179052A2 Serine proteases |
| 02/13/2002 | EP1179022A2 Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins |
| 02/13/2002 | EP1179020A1 Low-dose il-1beta-induced photoreceptor cell rescue without retinal dysplasia |
| 02/13/2002 | EP1179019A2 Immunogenic peptides derived from mage and the use thereof |
| 02/13/2002 | EP1179018A1 Interaction between the vhl tumour suppressor and hypoxia inducible factor, and assay methods relating thereto |
| 02/13/2002 | EP1179017A1 Expression of heparin-binding protein in recombinant mammalian cells |
| 02/13/2002 | EP1179015A1 Dna molecules encoding human clax proteins and their soluble fusion proteins |
| 02/13/2002 | EP1179012A1 Long lasting fusion peptide inhibitors or viral infection |
| 02/13/2002 | EP1179011A1 Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same |
| 02/13/2002 | EP1179010A2 Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins |
| 02/13/2002 | EP1179009A1 Prevention of dental caries |
| 02/13/2002 | EP1179008A2 Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application |
| 02/13/2002 | EP1179007A1 Self-assembling biomolecular structures |
| 02/13/2002 | EP1179006A2 Novel g-protein modulator (gpm) proteins and nucleic acid molecules and uses therefor |
| 02/13/2002 | EP1179002A1 Methods using mechanisms of action of aroa |
| 02/13/2002 | EP1179001A1 A splicing variant of human membrane-type matrix metalloproteinase-5 (mt-mmp5-l) |
| 02/13/2002 | EP1179000A2 Secreted proteins and uses thereof |
| 02/13/2002 | EP1178959A1 Alpha-amino-beta-sulfonyl hydroxamic acid compounds |
| 02/13/2002 | EP1178954A1 A structure-based approach to design inhibitors of protein-processivity factor interactions |
| 02/13/2002 | EP1178835A1 Compositions and methods for improving learning and memory |
| 02/13/2002 | EP1178834A1 Controlled release of growth factors from heparin containing matrices |
| 02/13/2002 | EP1178828A1 Death domain containing receptor 4 |
| 02/13/2002 | EP1178826A1 Immunotherapy of b-cell malignancies using anti-cd22 antibodies |
| 02/13/2002 | EP1178825A2 Adjuvant combination formulations |
| 02/13/2002 | EP1178821A1 Use of heparin-binding antagonists in the inhibition of bradykinin release |
| 02/13/2002 | EP1178820A1 Methods of modulating fabh activity |
| 02/13/2002 | EP1178819A2 Glutathione reductase for therapy and prophylaxis of aids |
| 02/13/2002 | EP1178818A1 A stable composition comprising epidermal growth factor as an active ingredient |
| 02/13/2002 | EP1178817A2 Molecular interactions in haematopoietic cells |
| 02/13/2002 | EP1178816A2 Materials for soft tissue augmentation and methods of making and using same |
| 02/13/2002 | EP1178815A1 Death domain containing receptors |
| 02/13/2002 | EP1178813A1 Method of stimulating growth in aquatic animals using growth hormones |
| 02/13/2002 | EP1178812A2 Conditioned cell culture medium compositions and methods of use |
| 02/13/2002 | EP1178803A2 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
| 02/13/2002 | EP1178796A1 Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases |
| 02/13/2002 | EP1178793A2 Stable solid pharmaceutical compositions containing enalapril maleate |
| 02/13/2002 | EP1178785A1 Compositions and methods for identifying antigens which elicit an immune response |
| 02/13/2002 | EP1178727A1 A therapeutic mixture useful in inhibiting lesion formation after vascular injury |
| 02/13/2002 | EP1178722A1 eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING |
| 02/13/2002 | EP1007671B1 Fanconi-gen ii |
| 02/13/2002 | EP0830142B1 Prrs (porcine reproductive and respiratory syndrome) virus vaccine |
| 02/13/2002 | EP0769957B1 Methods for treating motor deficits |
| 02/13/2002 | EP0759069B1 Beta taipoxin as a cell growth factor and method |
| 02/13/2002 | EP0724600B1 Process for preparing an inter-alpha-trypsine inhibitor concentrate for therapeutical use, and concentrate thus obtained |
| 02/13/2002 | EP0703786B1 Use of nona- and decapeptides in the preparation of a drug for the treatment of aids |
| 02/13/2002 | EP0693925B1 Production of a recombinant factor xa inhibitor of leech hirudo medicinalis |
| 02/13/2002 | EP0630257B1 Thymus-derived, immune-enhancing agent for therapeutic use in immunocompromised hosts |
| 02/13/2002 | EP0614379B1 Technetium-99m labeled peptides for imaging |
| 02/13/2002 | CN1335890A High efficiency mammalian gene expression vectors that contain exogenous promoter and entire 5' untranslated region in the upstream from start codon for inherent gene as transcription regulatory site |
| 02/13/2002 | CN1335889A Chimeric gene encoding the antigenic determinants of four proteins of L.INFANTUM |
| 02/13/2002 | CN1335888A OPG fusion protein compositions and methods |
| 02/13/2002 | CN1335887A Angiocidin: A Cys-Ser-Val-Thr-Cys-Gly specific tumor cell adhesion receptor |
| 02/13/2002 | CN1335884A Interluckin 17-like receptor protein |
| 02/13/2002 | CN1335854A Compositions and methods for controlling plant pests |
| 02/13/2002 | CN1335853A Alpha v beta b integrin inhibitors |
| 02/13/2002 | CN1335852A Novel depsipeptide compound |
| 02/13/2002 | CN1335776A Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia |
| 02/13/2002 | CN1335765A Polyol/oil suspensions for the sustained release of proteins |
| 02/13/2002 | CN1335764A Substrate composition and method of use for sequestration of skin irritants |
| 02/13/2002 | CN1335749A Method and compositions for treatment of cell proliferative disorders |
| 02/13/2002 | CN1335323A Maggot protein |
| 02/13/2002 | CN1335182A Insulin spray for oral cavity and its prepn process |
| 02/13/2002 | CN1335181A Antifungal medicine synergist and its prepn and application |
| 02/12/2002 | US6346613 An antisense oligonucleotide that hybridizes with a occludin mrna and disrupts tight junctions, to increase cell layer permeability to solutes and drugs |
| 02/12/2002 | US6346611 High affinity TGfβ nucleic acid ligands and inhibitors |
| 02/12/2002 | US6346608 MecB |
| 02/12/2002 | US6346607 A protein that induces apoptosis or binds cytochrome c; diagnosis and therapy for multiple sclerosis, parkinson's and alzheimer's diseases, cardiovascular diseases, strokes, toxin induced liver disease, cancer, lupus and herpes virus |
| 02/12/2002 | US6346606 A protein; diagnosis and therapy for tumor diseases, central nervous system diseases, glioblastomas, and breast cancer |
| 02/12/2002 | US6346604 Method for controlling conformation of cyclopentapeptide |
| 02/12/2002 | US6346602 Peptide mimics of the cytokine receptor common γ chain and methods and compositions for making and using the same |
| 02/12/2002 | US6346543 Administering baccatin derivative as anticarcinogenic agent |
| 02/12/2002 | US6346517 Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders |
| 02/12/2002 | US6346514 Pharmaceutical lysine-containing polypeptide compositions and methods of use thereof |
| 02/12/2002 | US6346513 Internal deletion of amino acids 741 through 1668; hemophilia treatment |
| 02/12/2002 | US6346512 Compounds and methods for modulating cell adhesion |
| 02/12/2002 | US6346510 Antiproliferative, anticarcinogenic and antitumor agents |